The Fact About BCAT-IN-4 That No One Is Suggesting
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives had been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyo